Vaccine maker Bharat Biotech’s Chikungunya vaccine has been administered to the first participant in Costa Rica, beginning the initial phase of clinical trials. The International Vaccine Institute (IVI) announced this.
IVI said – clinical trials are being done in partnership with Bharat Biotech
IVI said the trial is the beginning of a multi-center study led by it and in partnership with Bharat Biotech. It is funded by the Epidemic Preparedness Innovation Coalition (CEPI) with the support of the ‘Ind-CEPI’ mission of India’s Department of Biotechnology.
Krishna Ella said – Bharat Biotech’s vaccine was prepared after intensive research
Krishna Ella, Chairman and Managing Director, Bharat Biotech International Limited said, “Pandemic preparedness is an important step in public health care. Bharat Biotech’s vaccine has been prepared after extensive research. We thank the first volunteer from Costa Rica for participating in this study.’ The announcement follows CEPI’s US$3.5 billion plan launched in March 2021 to tackle future pandemics, including developing vaccines for various diseases, including chikungunya.